Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension
Aim. To assess atorvastatin lipid-lowering effect and tolerability at the initial stage of lipid-lowering treatment. Material and methods. The study included 47 patients (14 women, 33 men; mean age 55,6±11,6 years). Inclusion criteria were: verified coronary heart disease, CHD (stable effort angina,...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850041404591439872 |
|---|---|
| author | N. B. Amirov M. V. Potapova F. I. Ishkineev G. V. Tukhvatullina N. G. Efimova L. F. Mingazutdinova |
| author_facet | N. B. Amirov M. V. Potapova F. I. Ishkineev G. V. Tukhvatullina N. G. Efimova L. F. Mingazutdinova |
| author_sort | N. B. Amirov |
| collection | DOAJ |
| description | Aim. To assess atorvastatin lipid-lowering effect and tolerability at the initial stage of lipid-lowering treatment. Material and methods. The study included 47 patients (14 women, 33 men; mean age 55,6±11,6 years). Inclusion criteria were: verified coronary heart disease, CHD (stable effort angina, post-infarction cardiosclerosis), total cholesterol (TCH) level >5,0 mmol/l, low-density lipoprotein (LDL) CH level >3,0 mmol/l, triglycerides (TG) level _<3,5 mmol/l. CHD was verified in 31 patients (62%), including 17 with previous myocardial infarction (MI); 38 participants (76%) had arterial hypertension, 30 (60%) were overweight. All patients received atorvastatin (10 mg/d), individuals with CHD also received clopidogrel (75 mg/d). The follow-up period lasted for one month. After 14 days and one month of the therapy, lipid profile and liver function tests (LFT) were performed. Results. Thirty-day lipid-lowering therapy resulted in decreased TCH level (by 33,2%; p<0,01), reduced LDL-CH concentration (by 33,9%; p<0,05), elevated high-density lipoprotein (HDL) CH level (by 18,5%; p<0,05), and decreased atherogenicity index (by 38,4%; p<0,05). During one-month follow-up, no significant changes in LFT were observed. Conclusion. As early as during the first month of the treatment, lipid-lowering therapy with atorvastatin resulted in significant reduction in TCH, LDL-CH, and TG concentrations, together with increase in HDL-CH level. No effect on FLT was observed. |
| format | Article |
| id | doaj-art-e10317d5f15d44dda9b01760ddffbc30 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 1970-01-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-e10317d5f15d44dda9b01760ddffbc302025-08-20T02:55:48Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01251970-01-017755581198Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertensionN. B. Amirov0M. V. Potapova1F. I. Ishkineev2G. V. Tukhvatullina3N. G. Efimova4L. F. Mingazutdinova5Kazan State Medical University, Hospital No. 1, Tatar Republic Ministry of Internal Affairs, Kazan, Tatar RepublicKazan State Medical University, Hospital No. 1, Tatar Republic Ministry of Internal Affairs, Kazan, Tatar RepublicKazan State Medical University, Hospital No. 1, Tatar Republic Ministry of Internal Affairs, Kazan, Tatar RepublicKazan State Medical University, Hospital No. 1, Tatar Republic Ministry of Internal Affairs, Kazan, Tatar RepublicKazan State Medical University, Hospital No. 1, Tatar Republic Ministry of Internal Affairs, Kazan, Tatar RepublicKazan State Medical University, Hospital No. 1, Tatar Republic Ministry of Internal Affairs, Kazan, Tatar RepublicAim. To assess atorvastatin lipid-lowering effect and tolerability at the initial stage of lipid-lowering treatment. Material and methods. The study included 47 patients (14 women, 33 men; mean age 55,6±11,6 years). Inclusion criteria were: verified coronary heart disease, CHD (stable effort angina, post-infarction cardiosclerosis), total cholesterol (TCH) level >5,0 mmol/l, low-density lipoprotein (LDL) CH level >3,0 mmol/l, triglycerides (TG) level _<3,5 mmol/l. CHD was verified in 31 patients (62%), including 17 with previous myocardial infarction (MI); 38 participants (76%) had arterial hypertension, 30 (60%) were overweight. All patients received atorvastatin (10 mg/d), individuals with CHD also received clopidogrel (75 mg/d). The follow-up period lasted for one month. After 14 days and one month of the therapy, lipid profile and liver function tests (LFT) were performed. Results. Thirty-day lipid-lowering therapy resulted in decreased TCH level (by 33,2%; p<0,01), reduced LDL-CH concentration (by 33,9%; p<0,05), elevated high-density lipoprotein (HDL) CH level (by 18,5%; p<0,05), and decreased atherogenicity index (by 38,4%; p<0,05). During one-month follow-up, no significant changes in LFT were observed. Conclusion. As early as during the first month of the treatment, lipid-lowering therapy with atorvastatin resulted in significant reduction in TCH, LDL-CH, and TG concentrations, together with increase in HDL-CH level. No effect on FLT was observed.https://cardiovascular.elpub.ru/jour/article/view/1480dyslipidemiacoronary heart diseaselipid-lowering therapyatorvastatin |
| spellingShingle | N. B. Amirov M. V. Potapova F. I. Ishkineev G. V. Tukhvatullina N. G. Efimova L. F. Mingazutdinova Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension Кардиоваскулярная терапия и профилактика dyslipidemia coronary heart disease lipid-lowering therapy atorvastatin |
| title | Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension |
| title_full | Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension |
| title_fullStr | Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension |
| title_full_unstemmed | Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension |
| title_short | Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension |
| title_sort | dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension |
| topic | dyslipidemia coronary heart disease lipid-lowering therapy atorvastatin |
| url | https://cardiovascular.elpub.ru/jour/article/view/1480 |
| work_keys_str_mv | AT nbamirov dyslipidemiacorrectionwithatorvastatininpatientswithcoronaryheartdiseaseandarterialhypertension AT mvpotapova dyslipidemiacorrectionwithatorvastatininpatientswithcoronaryheartdiseaseandarterialhypertension AT fiishkineev dyslipidemiacorrectionwithatorvastatininpatientswithcoronaryheartdiseaseandarterialhypertension AT gvtukhvatullina dyslipidemiacorrectionwithatorvastatininpatientswithcoronaryheartdiseaseandarterialhypertension AT ngefimova dyslipidemiacorrectionwithatorvastatininpatientswithcoronaryheartdiseaseandarterialhypertension AT lfmingazutdinova dyslipidemiacorrectionwithatorvastatininpatientswithcoronaryheartdiseaseandarterialhypertension |